No Data
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $31
Positive Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Developments
OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth
H.C. Wainwright Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $40
Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Knight Therapeutics (OtherKHTRF) and OnKure Therapeutics (OKUR)
OnKure Therapeutics | 10-Q: Quarterly report
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
